Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.
Radich JP, Wall M, Branford S, Campbell CD, Chaturvedi S, DeAngelo DJ, Deininger M, Guinney J, Hochhaus A, Hughes TP, Kantarjian HM, Larson RA, Li S, Maegawa R, Mishra K, Obourn V, Pinilla-Ibarz J, Purkayastha D, Sadek I, Saglio G, Shrestha A, White BS, Druker BJ. Radich JP, et al. Among authors: maegawa r. Haematologica. 2023 Jun 1;108(6):1567-1578. doi: 10.3324/haematol.2022.281878. Haematologica. 2023. PMID: 36727397 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 36163930
[No title available]
[No authors listed] [No authors listed] PMID: 36163933
[No title available]
[No authors listed] [No authors listed] PMID: 36163937
Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States.
Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P. Atallah EL, et al. Among authors: maegawa r. J Health Econ Outcomes Res. 2022 Aug 4;9(2):19-29. doi: 10.36469/001c.36975. eCollection 2022. J Health Econ Outcomes Res. 2022. PMID: 35979528 Free PMC article.
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, Weber A, Avigan D, Chen YB, Nikiforow S, Ho VT, Cutler C, Alyea EP, Bachireddy P, Wu CJ, Ritz J, Streicher H, Ball ED, Bashey A, Soiffer RJ, Armand P. Davids MS, et al. Among authors: maegawa ro. Blood. 2020 Jun 11;135(24):2182-2191. doi: 10.1182/blood.2019004710. Blood. 2020. PMID: 32478814 Free PMC article. Clinical Trial.
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, Jacobsen ED, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia and Lymphoma Society. Davids MS, et al. Among authors: maegawa r. Lancet Haematol. 2019 Jan;6(1):e38-e47. doi: 10.1016/S2352-3026(18)30196-0. Epub 2018 Dec 14. Lancet Haematol. 2019. PMID: 30558987 Free PMC article. Clinical Trial.
15 results